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THE determination of serum enzymes has a well-established significance in
clinical diagnosis and in following the course of the disease. Heart and liver
diseases may be mentioned in this connection. From the point of view of cancer,
the use ofspecific enzyme reactions has not yet been proved in diagnosis and prog-
nosis except in a few exceptional cases (Bodansky, 1961; Douglas, 1963).
It is a common radiobiological phenomenon that enzyme activity increases
soon after irradiation of the organism (Bacq and Alexander, 1961). This has led
to the enzyme release theory i.e. the supposition that the prime cause ofradiation
injury is an alteration in the permeability of intracellular membrane structures,
as a result ofwhich enzymes are released from the cell (Bacq andAlexander, 1961).
In animal experiments, increased enzyme activity in tissue (Mitchell, 1960) and in
serum (Bacq and Alexander, 1961) has been proved after whole body irradiation.
According to Hughes (1958), the measurement of serum activity cannot, however,
give a quantitative estimation of tissue damage by irradiation, but is a good
qualitative early test.
Clinicalwork byKarcher (1962) and Karcher and Becker (1962) haspointed out
the possibility that the course of radiotherapy can be controlled by reference to
repeated serum enzyme determinations. Preliminary research showed that gluta-
mic oxaloacetic transaminase (GOT) increased in the serum regularly on the 6th
day of treatment, but it was soon made clear that this was an unspecific reaction
which also appeared after irradiation ofnormal tissue (Becker, Ebner and Karcher,
1959). These workers have since shown that, by means of the determination of
lactic acid dehydrogenase (LDH) and malic acid dehydrogenase (MDH) in serum,
the radiosensitivity of tumours and their growth and prognosis can be evaluated
(Karcher, 1962; Karcher and Becker, 1962). Phosphohexose isomerase (Bodan-
sky, 1961) and aldolase (King, 1962; Douglas, 1963) have also been mentioned as
a means of controlling treatment oftumours.
Because it is often impossible to estimate the radiation response of a deeply
located tumour by histological means, the biochemical method may have signifi-
cance in radiotherapy and possibly also in defining the length ofthe intervalin new
fractional regimes. Investigations were therefore begun in this clinic to study the
enzyme activityduring split-course radiotherapy.
MATERIAL AND METHODS
The material consists at present of 54 patients whose clinical diagnosis is given
in Table I. It includes 46 inoperable carcinomas and 8 operated carcinomas which
received post-operative radiotherapy. The radiation therapy was performedSERUM ENZYMES DURING RADIOTHERAPY
TABLE I.-Clinical Material
Cancer oflungoperable . . 29 cases
toperated . .7 ,
Mediastinal lymphomasrinoperable. 4
1,operated .1,
Cancer of oesophagus .. 7
Cancer of bladder . . 2
Cancer of colon . . . 2
Cancer of stomach . . 1
Lung metastases from chondrosar- 1
coma of femur
Total . . . . 54
either with a 35 MeV Betatron or with a 3000 c Cobalt unit six times a week as a
split-course therapy. A tumour dose of about 3000 r was followed by an interval
of two or three weeks, after which a further series of treatment 3000 r was given.
The total treatment time was 6 weeks in the majority of cases, but sometimes 5, 7
or 8 weeks. The daily tumour dose varied from 200-270 r. Six patients received
conventional continuous radiotherapy. Aldolase and LDH activity and in some
cases GOT and LAP (leucine aminopeptidase) activity was investigated. The
determinations were carried out once before treatment, after the 1st, 3rd and 6th
radiation treatment, and once a week subsequently. After the interval, determina-
tions were carried out in exactly the same way as at the start of the treatment.
During the interval period, enzyme investigations were not carried out because all
the patients were out-patients who went home during this period. For each
patient, two or three enzymes were determined simultaneously. A total of 1000
enzyme determinations have been carried out up to the present time.
Determinations of aldolase in Bruns units (Bruns, 1954), and LDH in Wrob-
lewski-La Due units (Wroblewski and La Due, 1955) were made using Boehringer
reagents, determinations of GOT in Sigma-Frankel units (Reitman and Frankel,
1955; Sigma Technical Bulletin, 1963) using Sigma reagents. LAP was determined
by the method ofGoldbarg and Rutenburg (1959).
RESULTS
GOT activity was determined in 12 patients. In all cases except one a carci-
noma ofthe colon-activity before the start oftreatment was normal. In only one
case, an anaplastic carcinoma of the lung, did activity increase to a pathological
level towards the end of continuous treatment. In all other cases, activity stayed
within normal limits, even though in two patients activity increased two-fold.
The rise noted by Becker, Ebner and Karcher (1959) after 6 treatments was not
noticed here.
LAP was determined in 16 patients in whom activity had been normal before
treatment. In 8 cases, activity increased by 50 per cent of the starting level, but
in no case during treatment did it rise to a pathological degree.
Aldolase was determined in 51 and LDH in all 54 patients. A more detailed
analysis ofthe material was made to discover in what relation and in how many of
eachdiagnosis groups the aldolase orLDH activityhadincreased before treatment,
in how many it increased during treatment, in how many it increased after the
interval and in how many cases activity continued normal throughout the treat-
ment period. Table II shows that in 24 patients enzyme activity remained normal
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TABLE II. Aldolase and LDH Activity During Radiotherapy
Normal activity
Elevated activity Iinereased activity throughout Increased activitv
before radiotherapy dluring radiotherapy radiotherapy after the interval
Aldo- Aldo- Aldo- Aldo-
lase- LDH Patienits lase LDH Patients lase LDH Patients lase LDH Patieint.;
Canccr of lung (inoper- 11 7 14 7 8 14 11 11 11 8 3 9
able)
Canicer of lung (operated) 2 2 3 1 ( 1 2 2 2 P 1 1
MKediastinal lvmphoma 01 1 1 ( 2 2 2 2 2 1 1 2
Mediastinal lymphoma (P (P (P ( (P ( 1 1 1 (P 0 IP
(operated)
Pulmonary metastases 0 (P (P (P PP (P 1 1 1 (P (0 0P
Cancer of oesophagus 01 ( 1 1 ( 1 5 (P 1 1 C'ancer of bladder PP (P ( (P (P (P 2 2 2 (P (P PP
Cancerof colon (P 1 1 (P (P (P 1 0 1 (P (P 0
Catnece of stomach PP 1 1 (P P (P (0 (P 0 ( P (P p
throughout treatment. The greatest chanige was found among carcinoma of the
lung patients who also formed the bulk of the material. An increase in the starting
level was recorded in 14 lung cancer patients, 7 of whom had large tumours or
tumours which had metastasised. The increase of enzyme activity was not shown
to depend on the histological type of the tumour. Usually, only one enzymic
activity was recorded as increasing to a pathological level and in several cases the
increase was very slight. In 7 cases out of 9, aldolase increased on the 3rd or 6th
day oftreatment, whilst in 8 cases out of 10, LDH increased on the 1st or 3rd day.
In several instances, the high level at the start oftreatment decreased to normal
during treatment, and in others activity increased at the start of treatment but
dropped rapidly. In some cases, an increase was noted during both stages of the
treatment.
To make clearer the possible relation between the radiation response and the
enzyme activity, chest X-ray pictures taken to record the reaction of lung cancer
were compared with the enzyme activity at different stages of the treatment. The
decreasing or disappearance of the tumours was not shown to have any regular
connection with the increase of enzyme activity. The increase occurred in only a
few cases which reacted favourably to radiation treatment. In 8 out of 10 cases
where activity increased, the primary result of treatment was satisfactory, whilst
in11 cases out of 19 where activity had not increased, the tumour had decreased
as a result of treatment. The field size was not seen to have any significance.
DISCUSSION
It has been shown that by determining the serum activity of LDH and MDH
at short intervals after the start of treatment, a typical enzyme curve can be
obtainedfrom whichthe radiosensitivity of the tumourin question can be evaluated
(Karcher, 1962). Tumours with a strong growth tendency and diseases of the
lymphoid system have originally a high LDH and MDH activity rate, and in these,
a strong increase in activity has been noted after the first treatment. In epithelial
carcinomas, a slower increase has been noted (Karcher and Becker, 1962). These
observations were based on 500 twin determinations on 150 patients.
In the present work a total of 1000 enzyme determinations (primarily of aldo-
lase and LDH) have been carried out on 54 patients. The determination of MDH
136SERUM ENZYMES DURING RADIOTHERAPY
has not been possible. The daily tumour dosage has been 200-270 r, whilst in
Karcher's series (1962) it was often 400-500 r. In one-third ofthe present material,
the aldolase and LDH activity has been at a pathologicallly high level preceding
treatment: in one-third, too, it has increased to a pathologically high level during
treatment. The enzyme activity in about half the patients did not increase above
the normal during the treatment period. This group included half of the lung
cancer patients and several patients with carcinoma of the oesophagus, carcinoma
of the bladder and carcinoma of the alimentary canal. The greatest changes were
recorded among the lung cancer patients.
The material included 7 operated carcinoma of the lung and 1 operated thy-
moma which received post-operative radiotherapy, because the metastatic media-
stinal glands had been removed during the operations. Ofthese 8 patients, in only
one did the enzyme activity rise above the normal during treatment. On the
other hand, activity increased in 14 of the 29 inoperable lung cancer cases. This
shows that the aldolase and LDH activity increases especially when tumour
tissue is irradiated. The rise in activity did not seem to depend on the histological
structure of the tumour nor on the field size used.
In some cases aldolase and LIDH activity was high when the patient began
treatment after the interval in split-course therapy. This canprobably be explained
by observations which have shown that, with split-course therapy, regression con-
tinues during the interval (Sambrook, 1962; Holsti, 1964). In some instances
aldolase increased during both phases of the treatment. Observations have as yet
led to no further conclusions with regard to split-course therapy.
It has not yet been possible to draw any unambiguous enzyme curve based on
the present material. In some instances the course corresponds to the results of
Karcher and Becker (1962), in which an increase in activity occurred in those cases
where there was a good or satisfactory radiation response, but discrepancies do
exist. In several cases activity did not increase although the tumour diminished
as much as in those other cases where an increase in activity had been recorded.
In some cases the high starting activity decreased to normal during treatment.
This corresponds to observations made during treatment of leukaemia (Bierman,
Hill, Emory, Reinhardt and Samuels, 1955).
On the basis of the present material, one can record, at least for the present,
that the increase of aldolase and LDH activity during radiotherapy usually occurs
in those patients whose tumours react favourably to radiation. The increase
occurs, however, inonly some ofthe cases. Anormalactivityduring treatmentdoes
not necessarily mean a poor radiation response. Karcher's statement (1962) that
the enzyme progression curve of the individual case, not the mean ofthe material
as a whole, is essential in judging a case, has certainly been proved accurate.
Discrepancies occur in so many cases, however, that a correct interpretation ofthe
facts still requires a great deal of work. It seems that enzymological diagnosis
during radiotherapy does not yet form a sufficiently sure and practicable radio-
biological test for the estimation of radiosensitivity.
SUMMARY
The serum activity of aldolase, lactic acid dehydrogenase (LDH), glutamic
acid transaminase (GOT) and leucine aminopeptidase (LAP) were determined in
patients undergoing split-course megavoltage radiotherapy for various malignant
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diseases. 1000 enzyme determinations were carried out on 54 patients. GOT and
LAP did not increase to a pathological level in 12 out of the 16 patients examined.
Aldolase and LDH increased to a pathological level in one-third of the whole
material, mainly in lung cancer patients, but hardly at all in patients suffering
from oesophageal cancer, cancer of the bladder, cancer of the colon or cancer of
the stomach.
The pathological increase ofaldolase and LDH usually coincided with a favour-
able primary reaction to radiotherapy. The low activity level of aldolase and
LDH during treatment can reveal nothing of the radiation response oflung cancer
patients because in 11 out of 19 cases thetumours decreased despite the lowenzyme
activity.
The increase in activity was not revealed as having a conniection with the
histological structure of the tumour or with the field size used.
Ofthe 8 patients who received post-operative radiotherapy after the removal of
the tumour, in only one was a slight increase in aldolase recorded towards the end
of treatment. LDH showed no increase whatsoever.
This investigation has been supported by a grant from the Sigrid Juselius
Foundation, Helsinki.
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